Dubé Pierre-André, Vachon Julien, Sirois Caroline, Roy Élise
Institut national de santé publique du Québec (Dubé, Vachon) Québec, Québec.
Département de médecine sociale et préventive (Sirois), Université Laval.
Can Pharm J (Ott). 2018 Oct 11;151(6):408-418. doi: 10.1177/1715163518805509. eCollection 2018 Nov-Dec.
Canada leads in opioid prescription and consumption rates, and this has resulted in high levels of opioid-related morbidity and mortality. Pharmacists' input could contribute significantly to understanding the disadvantages of opioid prescribing and dispensing and improving the service. This study aimed to examine the experiences of community pharmacists in relation to opioid prescribing and dispensing, with a focus on optimizing collaboration and communication.
An online survey was performed among pharmacists from the province of Quebec, Canada, in 2016. Pharmacists were eligible if registered and working in community pharmacies.
In all, 542 questionnaires were analyzed (participation rate of 8.1%). Pharmacotherapy-related problems were reported in at least 50% of opioid prescriptions: additional drug(s) required (reported by 30% of pharmacists), interaction(s) between opioid(s) and other drug(s) (16%), physician did not meet the general issuing standards for opioid prescriptions (26%) and patient had mild to moderate pain that was easily managed by a nonopioid analgesic (20%). Half of the patients were reported as requesting anticipated refills, possibly indicating abuse or poor pain control. Most pharmacists (89.6%) reported needing to contact physicians in 1 to 3 out of 10 opioid prescriptions, but many pharmacists (71.8%, often or very often) reported difficulties communicating with physicians.
Pharmacists' observations of pharmacotherapy-related problems and patients' unusual behaviours reveal a significant number of issues related to opioid prescribing and dispensing in an outpatient setting. Improved collaboration between physicians and pharmacists appears mandatory to address the issues reported in this study.
加拿大在阿片类药物处方率和消费率方面领先,这导致了与阿片类药物相关的高发病率和死亡率。药剂师的投入对于理解阿片类药物处方和配药的弊端以及改善服务可能会有很大帮助。本研究旨在调查社区药剂师在阿片类药物处方和配药方面的经验,重点是优化协作与沟通。
2016年对加拿大魁北克省的药剂师进行了一项在线调查。在社区药房注册并工作的药剂师符合条件。
共分析了542份问卷(参与率为8.1%)。至少50%的阿片类药物处方报告了药物治疗相关问题:需要额外用药(30%的药剂师报告)、阿片类药物与其他药物之间的相互作用(16%)、医生未达到阿片类药物处方的一般开具标准(26%)以及患者有轻度至中度疼痛,可通过非阿片类镇痛药轻松控制(20%)。据报告,一半的患者要求提前续方,这可能表明存在滥用或疼痛控制不佳的情况。大多数药剂师(89.6%)报告在每10份阿片类药物处方中有1至3份需要联系医生,但许多药剂师(71.8%,经常或非常经常)报告与医生沟通有困难。
药剂师对药物治疗相关问题和患者异常行为的观察揭示了门诊环境中与阿片类药物处方和配药相关的大量问题。医生和药剂师之间加强协作似乎是解决本研究中报告问题的必要条件。